Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Optimizing biological agents for ALL

Francesco Lanza • 17 Sep 2020
SOHO Italy 2020
Acute Lymphoblastic Leukemia Leukemia

Francesco Lanza, MD, Ravenna Hospital, Ravenna, Italy, discusses the use of biological agents in the treatment of acute lymphoblastic leukemia (ALL), and how these novel drugs can be optimized in order to improve their efficacy as well as patients outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Francesco Lanza

5:25
How the AML treatment landscape is changing with the introduction of novel targeted agents
Francesco Lanza • 24 Oct 2022
1:39
The importance of achieving CR before stem cell transplantation in patients with AML and ALL
Francesco Lanza • 24 Oct 2022
4:54
Monoclonal antibody combinations in ALL
Francesco Lanza • 17 Sep 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals